Curated News
By: NewsRamp Editorial Staff
June 24, 2024

Clene Presents Preliminary Data on CNM-Au8(R) as Potential Treatment for Rett Syndrome

Reddit Discuss on RedditDiscuss on Substack Discuss on Substack
Source News Release

TLDR

  • CNM-Au8 may prove to be a successful treatment for Rett Syndrome, expanding Clene's potential for treating multiple nervous system diseases.
  • CNM-Au8(R) is a first-in-class therapy that targets mitochondrial function and the NAD pathway to improve CNS cell survival and function.
  • CNM-Au8 has the potential to make a difference for millions of people living with difficult-to-treat neurologic diseases, offering hope for a better tomorrow.
  • New, preliminary data demonstrates the potential of CNM-Au8(R) as a treatment for Rett Syndrome, a severe, rare pediatric neurologic disorder.

Impact - Why it Matters

This news matters as it demonstrates the potential of a new treatment for Rett Syndrome, a severe pediatric neurologic disorder, and expands the scope of Clene's central thesis of developing CNM-Au8 as a treatment for multiple nervous system diseases.

Summary

Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. presented new data demonstrating the potential of CNM-Au8(R) as a treatment for Rett Syndrome, a rare pediatric neurologic disorder. CNM-Au8 showed neuroprotective effects and rescue of mitochondrial deficits in Rett patients. The company's vice president of translational medicine, Dr. Karen Ho, presented the data at the International Rett Syndrome Foundation 2024 Annual Meeting.

Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS and MS. CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress.

Source Statement

This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Presents Preliminary Data on CNM-Au8(R) as Potential Treatment for Rett Syndrome

blockchain registration record for the source press release.